Swellable hydrogel particles for controlled release pulmonary administration using propellant-driven metered dose inhalers

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 24, Issue 1, 2011, Pages 25-34

  Selvam, Parthiban ^a   El Sherbiny, Ibrahim M ^a   Smyth, Hugh D C ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

controlled release; curcumin; hydrogels; pressurized metered dose inhalers HFA227ea

Indexed keywords

CHITOSAN; FLUOROCARBON; MACROGOL; MICROSPHERE; NANOPARTICLE; POLYGLACTIN; PROPELLANT;

AEROSOL; ARTICLE; CONTROLLED DRUG RELEASE; DISPERSION; DRUG FORMULATION; DRUG STABILITY; HYDROGEL; IN VITRO STUDY; LUNG ALVEOLUS MACROPHAGE; METERED DOSE INHALER; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE PROPERTY;

ADMINISTRATION, INHALATION; AEROSOL PROPELLANTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHITOSAN; CURCUMIN; DELAYED-ACTION PREPARATIONS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HYDROCARBONS, FLUORINATED; HYDROGELS; LACTIC ACID; LUNG; METERED DOSE INHALERS; MICROSPHERES; NANOPARTICLES; PARTICLE SIZE; POLYETHYLENE GLYCOLS; POLYGLYCOLIC ACID;

EID: 79551591675     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2010.0830     Document Type: Article

References (47)

1. Patton JS, and Byron PR: Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6:67-74.
2. Lu D, and Hickey AJ: Pulmonary vaccine delivery. Expert Rev Vaccines. 2007;6:213-226.
3. Hickey AJ: Inhalation Aerosols. Informa Health Care, New York; 2007.
4. Smyth HD: Propellant-driven metered-dose inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2005; 2:53-74.
5. Laube BL: The expanding role of aerosols in systemic drug delivery, gene therapy, and vaccination. Respir Care. 2005;50:1161-1176.
6. Dellamary LA, Tarara TT, Smith DJ, Woelk CJ, Adractas A, Costello ML, Gill H, and Weers JG: Hollow porous particles in metered dose inhalers. Pharm Res. 2000;17:168-174.
7. Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, and Langer R: Large porous particles for pulmonary drug delivery. Science. 1997;276:1868-1872.
8. Yang Y, Bajaj N, Xua P, Ohnd K, Tsifanskye MD, and Yeo Y: Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials. 2009;30:1947-1953.
9. Koushik K, Dhanda D, Cheruvu N, and Kompella U: Pulmonary delivery of deslorelin: large-porous PLGA particles and HPbCD complexes. Pharm Res. 2004;21:1119-1126.
10. Wu L, Al-Haydari M, and da Rocha SR: Novel propellantdriven inhalation formulations: engineering polar drug particles with surface-trapped hydrofluoroalkane-philes. Eur J Pharm Sci. 2008;33:146-158.
11. Shoyele SA, and Cawthorne S: Particle engineering techniques for inhaled biopharmaceuticals. Adv Drug Deliv Rev. 2006;58:1009-1029.
12. Patton JS, Bukar J, and Nagarajan S: Inhaled insulin. Adv Drug Deliv Rev. 1999;35:235-247.
13. Wu L, and da Rocha SRP: Biocompatible and biodegradable copolymer stabilizers for hydrofluoroalkane dispersions: a colloidal probe microscopy investigation. Langmuir. 2007; 23:12104-12110.
14. Suh J, Choy KL, Lai SK, Suk JS, Tang BC, Prabhu S, and Hanes J. PEGylation of nanoparticles improves their cytoplasmic transport. Int J Nanomed. 2007;2:735-741.
15. Wang YY, Lai SK, Suk JS, Pace A, Cone R, and Hanes J. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl. 2008;47:9726-9729.
16. McGill S, Cuylear CL, Adolphi NL, Osinski M, and Smyth HDC: Magnetically responsive nanoparticles for drug delivery applications using low magnetic field strengths. Nanobioscience. 2009;8:33-42.
17. Grenha A, Seijo B, and Remuñán-López C: Microencapsulated chitosan nanoparticles for lung protein delivery. Eur J Pharm Sci. 2005;25:427-437.
18. Dickinson PA, Howells SW, and Kellaway IW: Novel nanoparticles for pulmonary drug administration. J Drug Target. 2001;9:295-302.
19. El-Sherbiny IM, McGill S, and Smyth HDC: Swellable microparticles as carriers for sustained pulmonary drug delivery. J Pharm Sci. 2010;99:2343-2356.
20. El-Sherbiny IM, and Smyth HDC: Novel cryomilled physically crosslinked biodegradable hydrogel microparticles as carriers for inhalation therapy. J Microencapsul. (in press).
21. Evora C, Soriano I, Rogers RA, Shakesheff KN, Hanes J, and Langer R: Relating the phagocytosis of microparticles by alveolar macrophages to surface chemistry: the effect of 1,2- dipalmitoylphosphatidylcholine. J Control Release. 1998;51: 143-152.
22. Gonzalez-Rothi RJ, Straub L, Cacace JL, and Schreier H: Liposomes and pulmonary alveolar macrophages: functional andmorphologic interactions. Expt Lung Res. 1991;17:687-705.
23. McDonald KJ, and Martin GP: Transition to CFC-free metered dose inhalers-into the new millennium. Int J Pharm. 2000;201:89-107.
24. Vervaet C, and Byron PR: Drug-surfactant-propellant interactions in HFA-formulations. Int J Pharm. 1999;186:13-30.
25. Blondino FE, and Byron PR: Surfactant dissolution and water solubilization in chlorine-free liquified gas propellants. Drug Dev Indust Pharmacy. 1998;24:935-945.
26. Courrier HM, Butz N, and Vandamme TF: Pulmonary drug delivery systems: recent developments and prospects. Crit Rev Ther Drug. 2002;19:228.
27. Smyth HDC, Brace G, Barbour T, Gallion J, Grove J, and Hickey AJ. Spray pattern analysis for metered dose inhalers: effect of actuator design. Pharm Res. 2006;23:1591-1596.
28. Smyth HDC, Beck VP, Williams D, and Hickey AJ: The influence of formulation and spacer device on the in vitro performance of solution chlorofluorocarbon-free propellantdriven metered dose inhalers. AAPS PharmSciTech 2004; 5:Article 7.
29. Smyth HDC: The influence of formulation variables on the performance of alternative propellant-driven metered dose inhalers. Adv Drug Deliv Rev. 2003;55:807-828.
30. Egan ME, Pearson M, Weiner SA, Rajendran V, Rubin D, Glöckner-Pagel J, Canny S, Du K, Lukacs GL, and Caplan MJ: Curcumin, a major constituent of turmeric, corrects cystic fibrosis defects. Science. 2004;304:600-602.
31. Ammon HPT, and Wahl MA: Pharmacology of Curcuma longa. Planta Medica. 1991;57:1-7.
32. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming- Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, and Hsieh CY: Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or premalignant lesions. Anticancer Res. 2001;21:2895-2900.
33. Huang M, Newmark HL, and Frenkel K: Inhibitory effects of curcumin on tumorigenesis in mice. J Cell Biochem. 1997;67: 26-34.
34. Sethi G, Sung B, and Aggarwal BB: The role of curcumin in modern medicine. Herbal Drugs: Ethnomed Modern Med. 2009;97-113.
35. Aggarwal BB, and Knight JV: Aerosol delivery of curcumin. Research Development Foundation, 2009; EP1658061.
36. Cartiera MS, Ferreira EC, Caputo C, Egan ME, Caplan MJ, and Saltzman WM: Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin. Mol Pharmaceut 2010;7:86-93.
37. Ochs M, Nyengaard JR, Jung A, Knudsen L, Voigt M, Wahlers T, Richter J, and Gundersen HJ: The number of alveoli in the human lung. Am J Respir Crit Care Med. 2004;169:120-124.
38. Ridder KB, Davies-Cutting CJ, and Kellaway IW: Surfactant solubility and aggregate orientation in hydrofluoroalkanes. Int J Pharm 2005;295:57-65.
39. Selvam P, Chokshi U, Wu L, Gouch A, Porcar L, and da Rocha SRP: Ethoxylated copolymer surfactants for the HFA134a-water interface: interfacial activity, aggregate microstructure and biomolecule uptake. Soft Matter. 2008;4: 357-366.
40. Rogueda P: Novel hydrofluoroalkane suspension formulations for respiratory drug delivery. Expert Opin Drug Deliv. 2005;2:625-638.
41. Wu L, Peguin RPS, and da Rocha SRP: Understanding solvation in hydrofluoroalkanes: ab initio calculations and chemical force microscopy. J Physiol Chem B 2007;111:8096-8104.
42. Peguin RPS, and da Rocha SRP: Solvent-solute interactions in hydrofluoroalkane propellants. J Physiol Chem B 2008; 112:8084-8094.
43. Chokshi U, Selvam P, Porcar L, and da Rocha SR: Reverse aqueous emulsions and microemulsions in HFA227 propellant stabilized by non-ionic ethoxylated amphiphiles. Int J Pharm 2009;369:176-184.
44. Wu L, Bharatwaj B, Panyam J, and da Rocha S: Core-shell particles for the dispersion of small polar drugs and biomolecules in hydrofluoroalkane propellants. Pharm Res. 2008;25:289-301.
45. Gupta A, Stein SW, and Myrdal PB: Balancing ethanol cosolvent concentration with product performance in 134abased pressurized metered dose inhalers. J Aerosol Med. 2003;6:167-174.
46. Shaikh J, Ankola D, Beniwal V, Singh D, and Kumar MR: Nanoparticle encapsulation improves oral bioavailability of curcumin by at least 9-fold when compared to curcumin administered with piperine as absorption enhancer. Eur J Pharmaceut Sci. 2009;37:223-230.
47. Peguin RPS, Wu L, and da Rocha SRP: The Ester group: how hydrofluoroalkane-philic is it? Langmuir 2007;23:8291-8294.